Skip to main content


Cost-Effectiveness Research

Featured

Conference Coverage
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for commercially insured patients with advanced ovarian cancer,…
Conference Coverage
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is…
News
KTE-X19 is a potentially cost-effective alternative to the current standard of care for relapsed/refractory MCL.
Videos
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition…
Videos
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy…
Back to Top